CRSP · CRISPR Therapeutics AG

$58.12 -1.69 (-2.83%) At close · Aug 20

Market Cap

$5.48B

96.69M

Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.

Equity Offering (ATM) Programs

Program Established	Last Amended	Capacity	Sold	Remaining	Runs Through	Source
2025-10	—	$600,000,000	$42,300,000 as of 2026-06-30	$557,200,000 as of 2026-06-30	—	10-Q , filed 2026-08-03

Cash spent on buybacks by quarter

Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.

Repurchase History

Fiscal Year Ended	Cash Spent	Shares	Avg Price	Source
2018-12-31	$57,000	—	—	10-K, filed 2021-02-16

Quarter Ended	Cash Spent	Shares	Avg Price	Source
2018-12-31	$0 Δ	—	—	10-K, filed 2021-02-16
2018-09-30	$7,000 Δ	—	—	10-Q, filed 2019-10-28

Key facts CIK 1674416 CUSIP H17182108 13F (30d) 463 filings 455 filers Visit website Investor relations